MRK vs NVS

Merck exhibits significant fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and a current price ($110.95) that trades at a massive premium to its Graham Number ($59.01) and Intrinsic Value ($50.96). While the company maintains impressive gross margins and ROE, these are offset by sharply negative earnings growth (-19.3% YoY) and a bearish technical trend. The combination of deteriorating financial health scores and aggressive insider selling suggests the stock is currently overvalued relative to its growth trajectory.

Novartis exhibits a stable financial foundation with a Piotroski F-Score of 6/9, yet it faces significant valuation headwinds. The stock is trading at a massive premium compared to its Graham Number ($61.62) and Intrinsic Value ($48.86), while current growth metrics are negative across both revenue (-0.70%) and earnings (-9.30%). While profitability remains elite with an ROE of 34.93%, the combination of a bearish technical trend (0/100) and deteriorating quarterly earnings surprises suggests limited near-term upside.